系统的翻译后修改全基因组识别了阿尔茨海默病的治疗点:来自多队列分析的证据
Xiaoming Wang1, Yuancheng Liu1, Juncai Fu1
1Department of Pathophysiology, School of Basic Medicine, Key Laboratory of Neurological Diseases of Hubei Province and National Education Ministry, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Innovation Center for Brain Medical Sciences of the Ministry of Education, Huazhong University of Science and Technology, Wuhan 430030, China.
The journal of prevention of Alzheimer's disease
|October 30, 2025
概括
这项研究使用后翻译修饰 (PTM) 分析和机器学习确定了不同的阿尔茨海默病 (AD) 亚型. TRIM47已成为AD药物发现的潜在治疗标.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 生物化学 生物化学
背景情况:
- 全球范围内阿尔茨海默氏病 (AD) 发病率正在上升,造成重大社会和经济负担.
- 目前对阿尔茨海默病的治疗方法不会改变疾病的进展,这凸显了对新型治疗策略的需求.
研究的目的:
- 为了识别阿尔茨海默病 (AD) 的不同亚型.
- 探索后翻译修改 (PTMs) 在AD病变发生过程中的作用.
- 为了确定AD治疗的潜在治疗点.
主要方法:
- 共识聚类和权重基因共同表达网络分析 (WGCNA) 用于识别AD亚型和关键基因.
- 机器学习算法被用来识别枢纽基因并开发一个预测得分 (PTM.score).
- 对21个翻译后修饰 (PTM) 进行了全基因组分析.
主要成果:
- 基因本体学 (GO) 和KEGG分析显示,PTM在AD和相关途径中至关重要.
- PTM与AD生物标志物 (粉样β42,布拉克阶段) 和玛/β分泌酶活性有显著的相关性.
- 一个PTM.score在脑 (AUC:0.859) 和血液 (AUC:0.898) 样本中显示了AD的高预测准确性.
- 确定TRIM47和LNX1是潜在的药物点,TRIM47与CSF Aβ和p-tau水平相关.
结论:
- 这项研究提高了对AD机制的理解,并确定了潜在的治疗途径.
- TRIM47被强调为开发创新的阿尔茨海默病治疗方法的有希望的目标.
相关概念视频
Alzheimer's Disease: Treatment
801
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
801
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K


